EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study

Mehmet Ergün, Anouk M E Jansen iD, Luuk B Hilbrands iD, Elizabeth de Kort iD, Henricus Kunst, Monique H E Reijers, Jeroen A Schouten, Paul E Verweij iD, Roger J M Brüggemann iD

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae139 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Mehmet Ergün und 8 weiteren Autor:innen. Beteiligte Einrichtung: Radboudumc-CWZ Center of Expertise for Mycology, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Pyridines, Triazoles, Nitriles, Antifungal Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Isavuconazole is a relatively new antifungal agent indicated for the management of various invasive fungal diseases (IFDs), including invasive aspergillosis. Information on real-world experience with isavuconazole is scarce. This retrospective observational study aimed to describe the usage of isavuconazole in clinical practice with an in-depth evaluation of individual isavuconazole exposure.

Methods

Patients treated with isavuconazole were evaluated based on retrospective data, including therapeutic drug monitoring (TDM) data and efficacy and safety data. Additionally, we calculated the individual isavuconazole exposure described by the average AUC24 over the first 7 days of treatment by means of non-linear mixed-effects modelling and compared this with the currently desired lower target AUC of 60 mg·h/L.

Results

Ninety-nine patients treated with isavuconazole were evaluated. In our real-life cohort, isavuconazole was often deployed off-label in patients with non-classical host factors and infections with non-Aspergillus and non-Mucorales species. Isavuconazole was most often chosen for its safety profile, even after prior triazole treatment with manifestations of toxicity. TDM and subsequent dosage adjustments were frequently performed. The individual average AUC24 over 7 days was above 60 mg·h/L in 29 out of 77 (37.7%) patients.

Conclusions

This overview provides practical insights that can aid clinicians in the management of their patients with IFD. Our study shows that isavuconazole was used in a diverse patient population and was well tolerated overall. Individual isavuconazole exposure reflected by the average AUC24 over the first 7 days of treatment was generally low and variable. Dosage adjustments following TDM were frequently performed. Our experience shows that isavuconazole is a feasible alternative after prior azole treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridinesTriazolesNitrilesAntifungal AgentsInvasive Fungal InfectionsHumansRetrospective StudiesFemaleMaleMiddle AgedAgedAdultDrug MonitoringAged, 80 and overYoung Adult

Substanzen

isavuconazolePyridinesTriazolesNitrilesAntifungal Agents

Autor:innen und Institutionen

  • Radboudumc-CWZ Center of Expertise for Mycology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Haematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Otorhinolaryngology, Dutch Academic Alliance Skull Base Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.

ORCID-Profile: Anouk M E Jansen, Luuk B Hilbrands, Elizabeth de Kort, Paul E Verweij, Roger J M Brüggemann

Förderung

  • Pfizer

Zitieren

APA

Ergün, M., Jansen, A. M. E., Hilbrands, L. B., de Kort, E., Kunst, H., Reijers, M. H. E., Schouten, J. A., Verweij, P. E., & Brüggemann, R. J. M. (2024). Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae139

Vancouver

Ergün M, Jansen AME, Hilbrands LB, de Kort E, Kunst H, Reijers MHE, et al. Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae139

BibTeX
@article{Ergn2024,
  author = {Ergün, Mehmet and Jansen, Anouk M E and Hilbrands, Luuk B and de Kort, Elizabeth and Kunst, Henricus and Reijers, Monique H E and Schouten, Jeroen A and Verweij, Paul E and Brüggemann, Roger J M},
  title = {Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae139}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche